Benzinga's Top Upgrades, Downgrades For July 2, 2020

Loading...
Loading...

Upgrades

  • For Forterra Inc FRTA, SunTrust Robinson Humphrey upgraded the stock from Hold to Buy. In the first quarter, Forterra showed an EPS of ($0.22), compared to ($0.39) from the year-ago quarter. The stock has a 52-week-high of $15.42 and a 52-week-low of $3.45. Forterra's stock last closed at $11.86 per share.
  • B of A Securities changed the rating for Hibbett Sports Inc HIBB from Underperform to Buy. Hibbett Sports earned $0.31 in the first quarter, compared to $1.61 in the year-ago quarter. The stock has a 52-week-high of $30.98 and a 52-week-low of $7.33. Hibbett Sports's stock last closed at $20.78 per share.
  • Cowen & Co. changed the rating for Akamai Technologies Inc AKAM from Market Perform to Outperform. For the first quarter, Akamai Technologies had an EPS of $1.20, compared to year-ago quarter EPS of $1.10. The stock has a 52-week-high of $108.25 and a 52-week-low of $75.18. Akamai Technologies's stock last closed at $106.33 per share.
  • Needham changed the rating for TTM Technologies Inc TTMI from Hold to Buy. In the first quarter, TTM Technologies showed an EPS of $0.18, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $16.25 and a 52-week-low of $8.06. TTM Technologies's stock last closed at $11.32 per share.
  • Bradesco upgraded the stock for Arcos Dorados Holdings Inc ARCO from Neutral to Outperform. In the first quarter, Arcos Dorados Holdings showed an EPS of ($0.26), compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $8.41 and a 52-week-low of $2.96. Arcos Dorados Holdings's stock last closed at $4.27 per share.
  • Morgan Stanley changed the rating for Avis Budget Group Inc CAR from Equal-Weight to Overweight. In the first quarter, Avis Budget Gr showed an EPS of ($1.40), compared to ($0.78) from the year-ago quarter. The stock has a 52-week-high of $52.98 and a 52-week-low of $6.35. Avis Budget Gr's stock last closed at $22.48 per share.
  • Credit Suisse upgraded the stock for EQT Corp EQT from Neutral to Outperform. EQT earned $0.14 in the first quarter, compared to $0.83 in the year-ago quarter. The stock has a 52-week-high of $17.16 and a 52-week-low of $4.21. EQT's stock last closed at $11.44 per share.
  • For Liberty Global PLC LBTYA, Redburn upgraded the stock from Neutral to Buy. For the first quarter, Liberty Global had an EPS of $1.50, compared to year-ago quarter EPS of ($0.43). The stock has a 52-week-high of $28.62 and a 52-week-low of $15.23. Liberty Global's stock last closed at $21.88 per share.
  • Jefferies changed the rating for Nu Skin Enterprises Inc NUS from Hold to Buy. For the first quarter, Nu Skin Enterprises had an EPS of $0.36, compared to year-ago quarter EPS of $0.77. The stock has a 52-week-high of $50.98 and a 52-week-low of $12.30. Nu Skin Enterprises's stock last closed at $38.42 per share.

 

Downgrades

  • Craig-Hallum changed the rating for FormFactor Inc FORM from Buy to Hold. In the first quarter, FormFactor showed an EPS of $0.33, compared to $0.20 from the year-ago quarter. The stock has a 52-week-high of $30.99 and a 52-week-low of $15.03. FormFactor's stock last closed at $29.32 per share.
  • For Franklin Electric Co Inc FELE, DA Davidson downgraded the stock from Buy to Neutral. In the first quarter, Franklin Electric showed an EPS of $0.24, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $61.49 and a 52-week-low of $41.25. Franklin Electric's stock last closed at $51.25 per share.
  • Goldman Sachs changed the rating for Livongo Health Inc LVGO from Buy to Neutral. In the first quarter, Livongo Health earned $0.03. The stock has a 52-week-high of $79.10 and a 52-week-low of $15.12. Livongo Health's stock last closed at $74.41 per share.
  • Piper Sandler changed the rating for American Equity Investment Life Holding Co AEL from Overweight to Neutral. For the first quarter, American Equity Inv had an EPS of $1.67, compared to year-ago quarter EPS of $0.97. The stock has a 52-week-high of $34.16 and a 52-week-low of $9.07. American Equity Inv's stock last closed at $23.32 per share.

 

Initiations

  • For FLIR Systems Inc FLIR, Canaccord Genuity initiated coverage, by setting the current rating at Buy. In the first quarter, FLIR Systems showed an EPS of $0.42, compared to $0.53 from the year-ago quarter. The stock has a 52-week-high of $59.44 and a 52-week-low of $23.85. FLIR Systems's stock last closed at $40.86 per share.
  • With a rating of Buy, Deutsche Bank initiated coverage on Fastenal Co FAST. The price target is set at $50.00 for Fastenal. In the first quarter, Fastenal showed an EPS of $0.35, compared to $0.68 from the year-ago quarter. The stock has a 52-week-high of $43.20 and a 52-week-low of $26.71. Fastenal's stock last closed at $43.01 per share.
  • HC Wainwright & Co. initiated coverage on Applied DNA Sciences Inc APDN with a Buy rating. The price target for Applied DNA Sciences is set at $18.00. In the second quarter, Applied DNA Sciences showed an EPS of ($0.79), compared to ($0.08) from the year-ago quarter. The stock has a 52-week-high of $19.69 and a 52-week-low of $0.17. Applied DNA Sciences's stock last closed at $7.75 per share.
  • With a rating of Equal-Weight, Morgan Stanley initiated coverage on Avangrid Inc AGR. The price target is set at $46.00 for Avangrid. Avangrid earned $0.76 in the first quarter, compared to $0.71 in the year-ago quarter. The stock has a 52-week-high of $57.24 and a 52-week-low of $35.62. Avangrid's stock last closed at $43.15 per share.
  • With a rating of Overweight, Morgan Stanley initiated coverage on Karyopharm Therapeutics Inc KPTI. The price target is set at $34.00 for Karyopharm Therapeutics. Karyopharm Therapeutics earned ($0.78) in the first quarter, compared to ($1.09) in the year-ago quarter. The stock has a 52-week-high of $29.61 and a 52-week-low of $5.42. Karyopharm Therapeutics's stock last closed at $19.25 per share.
  • With a rating of Overweight, JP Morgan initiated coverage on Rocket Pharmaceuticals Inc RCKT. The price target is set at $38.00 for Rocket Pharmaceuticals. In the first quarter, Rocket Pharmaceuticals showed an EPS of ($0.45), compared to ($0.43) from the year-ago quarter. The stock has a 52-week-high of $27.59 and a 52-week-low of $9.01. Rocket Pharmaceuticals's stock last closed at $20.50 per share.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Penny StocksUpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsInitiationstop upgrades
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...